Electron Kebebew, M.D., F.A.C.S.

Senior Investigator

Endocrine Oncology Branch

NCI/CCR

Building 10 - Hatfield CRC, Room 4-5952
Bethesda, MD 20892-1201

301-496-5049

kebebewe@mail.nih.gov

Research Topics

Our research is focused on understanding the genetic/genomic/epigenetic changes that drive endocrine cancer growth and metastases, and to use this knowledge to improve diagnosis and prognostication, and treatment for these cancers. Currently, we have three main areas of investigations: 1) identification of altered pathways in endocrine neoplasms using pangenomic analysis of human samples and characterizing the functions of these altered genes/pathways using in vitro and in vivo models, 2) discovery of therapeutic targets and novel anticancer agents for endocrine cancers, and 3) genetic studies in familial non-medullary thyroid cancer to identify the susceptibility gene(s) and its application to improve screening and diagnosis of at-risk individuals.

Biography

Dr. Kebebew received his bachelor's degree from the University of California, Los Angeles, in chemical engineering. He completed his medical training, surgical residency and NCI T32 Surgical Oncology Basic Science fellowship at the University of California, San Francisco. Dr. Kebebew joined the surgical faculty at the University of California, San Francisco, in 2002. In 2009, Dr. Kebebew was recruited to be the Head of the Endocrine Oncology Section in the Surgery Branch. In 2012, he became Chief of the newly established Endocrine Oncology Branch. Dr. Kebebew has published over 300 articles, chapters and textbooks. He has received awards from the American Cancer Society, American Association for Cancer Research, American Thyroid Association, American Association of Endocrine Surgeons, and International Association of Endocrine Surgeons. His laboratory investigates the genetic/genomic changes associated with endocrine cancers with the ultimate goal of identifying therapeutic targets and novel anticancer agents for endocrine cancers, and diagnostic and prognostic markers for endocrine tumors. Dr. Kebebew is a Fellow of the American College of Surgeons, an internationally recognized expert in endocrine surgery, and has performed more than 3,000 operations on the adrenal, pancreas, parathyroid and thyroid.

Selected Publications

  1. Mehta A, Zhang L, Boufraqech M, Liu-Chittenden Y, Zhang Y, Patel D, Davis S, Rosenberg A, Ylaya K, Aufforth R, Li Z, Shen M, Kebebew E. Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer. Clin Cancer Res. 2015;21(18):4123-32.

  2. Boufraqech M, Nilubol N, Zhang L, Gara SK, Sadowski SM, Mehta A, He M, Davis S, Dreiling J, Copland JA, Smallridge RC, Quezado MM, Kebebew E. miR30a inhibits LOX expression and anaplastic thyroid cancer progression. Cancer Res. 2015;75(2):367-77.

  3. Gara SK, Wang Y, Patel D, Liu-Chittenden Y, Jain M, Boufraqech M, Zhang L, Meltzer PS, Kebebew E. Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples. Nucleic Acids Res. 2015;43(19):9327-39.

  4. Zhang L, Zhang Y, Mehta A, Boufraqech M, Davis S, Wang J, Tian Z, Yu Z, Boxer MB, Kiefer JA, Copland JA, Smallridge RC, Li Z, Shen M, Kebebew E. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget. 2015;6(11):9073-85.

  5. Sadowski SM, Millo C, Neychev V, Aufforth R, Keutgen X, Glanville J, Alimchandani M, Nilubol N, Herscovitch P, Quezado M, Kebebew E. Feasibility of Radio-Guided Surgery with ⁶⁸Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2015;22 Suppl 3:S676-82.


This page was last updated on June 15th, 2017